Patents by Inventor David Bumcrot

David Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11141493
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 12, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Patent number: 11028394
    Abstract: Disclosed herein are genome editing systems and compositions that target a cystic fibrosis transmembrane conductance regulator (CFTR) gene and a sodium channel epithelial 1 alpha (SCNN1A) gene, comprising a Cas9 molecule, and a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a CFTR gene or a SCNN1A gene, and cells comprising such genome editing systems and compositions. Also provided are methods for using the genome editing systems, compositions, and cells for genome engineering (e.g., altering a CFTR gene and/or a SCNN1A gene), and for preventing or treating Cystic Fibrosis (CF) and CF-like disease.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 8, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Deepak Reyon, Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • Patent number: 11028388
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 8, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan L. Maeder, David A. Bumcrot
  • Publication number: 20210161997
    Abstract: The present invention provides methods and compositions for the treating a patient with a genetic disease, such as fibronectin glomerulopathy, hereditary coproporphyria and others. Methods and compositions are also provided for modulating the disease-associated gene(s) by altering gene signaling networks.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 3, 2021
    Inventors: David A. Bumcrot, Alfica Sehgal, Alla Sigova, Vaishnavi Rajagopal, Brian Schwartz, Cynthia Smith
  • Patent number: 11001844
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 11, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Publication number: 20210118524
    Abstract: Disclosed herein are methods for linking non-coding variants and candidate genes that are associated with one another through long-range chromatin interactions. Thus, these non-coding variants may be involved in the expression of a candidate gene and therefore, serve as possible therapeutic targets for treating diseases in which the expression fo the candidate gene is dysreguated. A non-coding variant can be linked to a candidate gene by analyzing datasets including chromatin accessibility data (e.g., ATAC-seq data), protein-chromatin binding site pairing data, and/or chromatin contact profile. For example, a non-coding variant can be linked to a candidate gene by identifying an enhancer-promoter loop through a long range chromatin interaction. As another example, a non-coding variant can be linked to a candidate gene through a statistical eQTL analysis.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 22, 2021
    Inventors: Yuting Liu, Asher Schachter, Alla Sigova, David A. Bumcrot, Iris Grossman
  • Publication number: 20210114996
    Abstract: Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 22, 2021
    Inventors: Alfica Sehgal, Alla A. Sigova, Igor Zlobine, Brian E. Schwartz, David A. Bumcrot, Vaishnavi Rajagopal, Yun Joon Jung, Yuichi Nishi
  • Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Publication number: 20210061837
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: April 5, 2019
    Publication date: March 4, 2021
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • Patent number: 10935917
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina 1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina 1.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: March 2, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Publication number: 20210041823
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • Publication number: 20200316038
    Abstract: The present invention provides methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.
    Type: Application
    Filed: October 9, 2018
    Publication date: October 8, 2020
    Inventors: Alfica Sehgal, Alla A. Sigova, Igor Zlobine, Brian E. Schwartz, David A. Bumcrot
  • Publication number: 20200255833
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 13, 2020
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Publication number: 20200208128
    Abstract: The present invention provides methods and compositions for the treating a patient with one or more conditions associated with PNPLA3 such as nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH), and/or alcoholic liver disease (ALD). Methods and compositions are also provided for modulating the expression of the PNPLA3 gene in a cell by altering gene signaling networks.
    Type: Application
    Filed: August 14, 2018
    Publication date: July 2, 2020
    Inventors: David A. Bumcrot, Alfica Sehgal, Alla Sigova, Brian Elliott Schwartz, Gavin Whissell
  • Patent number: 10669544
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 2, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • Publication number: 20200017849
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: February 19, 2019
    Publication date: January 16, 2020
    Inventors: Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
  • Publication number: 20190354055
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 21, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Publication number: 20190292595
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 6, 2019
    Publication date: September 26, 2019
    Inventors: Dinah Sah, David A. Bumcrot, Alfica Sehgal
  • Publication number: 20190264207
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 29, 2019
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Publication number: 20190249157
    Abstract: Disclosed herein are genome editing systems and genetic constructs that targets a herpes simplex virus (HSV) viral gene comprising one Cas9 molecule, and a gRNA molecule, and compositions and cells comprising such genome editing systems and genetic constructs. Also provided are methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering (e.g., altering a HSV viral gene), and for preventing, treating or reducing HSV infection.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Applicants: EDITAS MEDICINE, INC., DUKE UNIVERSITY
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen